RA
Rosalind Advisors Portfolio holdings
AUM
$207M
This Quarter Return
+8.64%
1 Year Return
+62.29%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$207M
AUM Growth
+$207M
(+0.69%)
Cap. Flow
-$1.6M
Cap. Flow
% of AUM
-0.77%
Top 10 Holdings %
Top 10 Hldgs %
63.59%
Holding
43
New
4
Increased
7
Reduced
9
Closed
6
Top Buys
| 1 |
Cytokinetics
CYTK
|
$13.2M |
| 2 |
Rezolute
RZLT
|
$7.77M |
| 3 |
CG Oncology
CGON
|
$5.02M |
| 4 |
Delcath Systems
DCTH
|
$4M |
| 5 |
Fennec Pharmaceuticals
FENC
|
$2.18M |
Top Sells
| 1 |
Abeona Therapeutics
ABEO
|
$8.6M |
| 2 |
UroGen Pharma
URGN
|
$5.58M |
| 3 |
Nuvation Bio
NUVB
|
$4.31M |
| 4 |
IDEAYA Biosciences
IDYA
|
$3.97M |
| 5 |
Verastem
VSTM
|
$2.49M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Delcath Systems
DCTH
$385M
| $33M | 15.65% | 3,300,389 +400,000 | +14% | +$4M |
|
|
2
Fennec Pharmaceuticals
FENC
$247M
| $17M | 8.05% | 2,045,644 +262,800 | +15% | +$2.18M |
|
|
3
Cytokinetics
CYTK
$4.23B
| $13.2M | 6.27% | +400,000 | New | +$13.2M |
|
4
Ocular Therapeutix
OCUL
$2.12B
| $11.3M | 5.36% | 1,218,700 | – | – |
|
|
5
IDEAYA Biosciences
IDYA
$2.15B
| $10.7M | 5.09% | 511,132 -188,868 | -27% | -$3.97M |
|
6
Xeris Biopharma Holdings
XERS
$1.26B
| $10.1M | 4.77% | 2,155,594 -340,392 | -14% | -$1.59M |
|
7
Viridian Therapeutics
VRDN
$1.5B
| $9.79M | 4.64% | 700,000 +105,000 | +18% | +$1.47M |
|
|
VRNA
8
Verona Pharma
VRNA
$9.16B
| $9.46M | 4.48% | 100,000 | – | – |
|
|
9
Verastem
VSTM
$569M
| $8.48M | 4.02% | 2,043,563 -600,954 | -23% | -$2.49M |
|
10
Replimune Group
REPL
$422M
| $8.36M | 3.96% | 900,000 +50,000 | +6% | +$465K |
|
11
MediWound
MDWD
$182M
| $7.88M | 3.74% | 407,061 -99,832 | -20% | -$1.93M |
|
12
Myomo
MYO
$39.7M
| $7.77M | 3.68% | 3,595,788 +892,127 | +33% | +$1.93M |
|
|
13
Rezolute
RZLT
$619M
| $7.77M | 3.68% | +1,741,211 | New | +$7.77M |
|
|
14
UroGen Pharma
URGN
$900M
| $7.43M | 3.52% | 542,366 -407,634 | -43% | -$5.58M |
|
|
CYBN
15
Cybin
CYBN
$176M
| $6.8M | 3.23% | 810,918 | – | – |
|
16
Savara
SVRA
$567M
| $6.05M | 2.87% | 2,654,944 | – | – |
|
17
InspireMD
NSPR
$102M
| $5.2M | 2.46% | 2,289,099 +14,109 | +0.6% | +$32K |
|
|
18
CG Oncology
CGON
$2.04B
| $5.02M | 2.38% | +192,974 | New | +$5.02M |
|
|
PROF
19
Profound Medical
PROF
$134M
| $4.08M | 1.94% | 692,185 | – | – |
|
20
Pharvaris
PHVS
$1.39B
| $3.94M | 1.87% | 223,627 | – | – |
|
21
PolyPid
PYPD
$53.3M
| $3.44M | 1.63% | 975,462 -42,559 | -4% | -$150K |
|
22
MindMed
MNMD
$676M
| $2.73M | 1.29% | 420,000 | – | – |
|
23
KalVista Pharmaceuticals
KALV
$678M
| $1.78M | 0.85% | 157,725 -146,139 | -48% | -$1.65M |
|
24
Trevi Therapeutics
TRVI
$883M
| $1.64M | 0.78% | 300,000 -312,901 | -51% | -$1.71M |
|
|
CMPS
25
Compass Pathways
CMPS
$424M
| $1.35M | 0.64% | 482,651 -340,635 | -41% | -$954K |
|